CD274 and ovarian carcinoma: • 75% high-grade serous• Advanced recurrent ovarian cancer• Cohort A: 1–3 prior lines with PFI or TFI 3–12 months• Cohort B: 4–6 prior lines with PFI or TFI ≥3 months• Platinum-resistant recurrent (38%)• PD-L1 expression assessed